Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05914363
Other study ID # 28307
Secondary ID 424/4
Status Recruiting
Phase N/A
First received
Last updated
Start date April 12, 2023
Est. completion date December 2024

Study information

Verified date June 2024
Source London School of Hygiene and Tropical Medicine
Contact Rachel Pullan, PhD
Phone +44 777 2241148
Email rachel.pullan@lshtm.c.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this intervention study is to learn about the impact of household flooring on health in rural Kenya, and test whether providing an improved (cement stabilised, washable) floor improves the health of children and their care providers. The main questions the study aims to answer are: - What is the effect of providing a sealed, washable floor on the prevalence of infections that cause diarrhoea, intestinal worms and sand flea infections? - To what extent does the intervention reduce contamination of floors with pathogens within the home? - What is its effect of the intervention on the wellbeing of caregivers and children? - Over the course of a year, do the new floors remain undamaged, with no cracks? - Do participants living with the new floors, and the masons that helped to install the floors, like them and feel they are practical and affordable? The study will involve a trial, where half of the recruited households will be randomly chosen to receive the new floor in addition to some support on how to care for the floor and keep it clean. The other half of households will not receive anything at first, but at the end of the research project will also receive a new floor. Before the new floors are installed, the investigators will make several assessments in all study households. These will include a survey to measure household characteristics; a stool survey, to measure how many people are infected with diarrhoea-causing microorganisms and parasitic worms; a jigger flea examination among children; wellbeing assessments among children and caregivers; and soil sampling to identify microorganisms on the floor of the household. When households receive the new floor, participants will have to move out of their house for up to 7 days during installation. Participants will also be asked to attend some group meetings to discuss ways of taking care of the floor and keeping it clean. Assessments will be repeated 12 months after the floor has been delivered, and additional interviews will be held with a small number of randomly selected participants. Throughout the 12 months following delivery of the intervention, investigators will make unannounced visits to households to check the condition of the floor. Participants will also be offered treatment for parasitic worm infections after assessments have been completed at the start and end of the project.


Description:

Earthen floors are often damp or dusty and difficult to clean, providing an ideal environment for faecal pathogens and parasites. Cross-sectional studies have revealed associations between household flooring and health outcomes, but robust experimental evidence is scant. This study will evaluate the impact of an improved household flooring intervention on enteric infections, soil-transmitted helminth (STH) infections, and tungiasis through implementation of a cluster-randomised trial in two rural settings in Kwale and Bungoma Counties, Kenya. The primary aim of this study is to evaluate the effectiveness of an improved flooring intervention in reducing the burden of enteric infections, STH and tungiasis in participating households through implementation of a randomised controlled trial (RCT) in two distinct settings in rural Kenya. The primary objectives are to quantify impact on the prevalence of enteric infections, STH infections, and tungiasis. Secondary objectives include assessing impact on the wellbeing of caregivers and children, self-report gastrointestinal illness in children, and the extent to which entero-pathogen and parasitic contamination of floors is reduced within the home. We will also examine the differential effects across community and household contexts (including water, sanitation, and hygiene (WASH) infrastructure, animal husbandry, user adherence and study site). Lastly, we deliver a process evaluation to determine the practicality, acceptability, costs, and durability of the improved flooring intervention and how environmental, installation, and use factors affect these. In total, 440 clusters (households) across both sites are allocated to either control or intervention group, in which a low-cost, sealed, washable cement-based floor is installed in all eligible buildings of the dwelling, alongside a floor care guide provided during an induction meeting. Prevalence of enteric infections in children under 5 years will be assessed via stool surveys and PCR; prevalence of tungiasis infection in children 1-14 years based on clinical exam; and prevalence of STH infection in all household members over 1 year assessed via Kato-Katz. Following the 12-month implementation period and final assessments, control households will be offered improved floors.


Recruitment information / eligibility

Status Recruiting
Enrollment 2200
Est. completion date December 2024
Est. primary completion date August 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Household with a child under 5 years of age that meets structural criteria (unimproved earthen flooring throughout, structurally sound), with members willing to temporarily relocate. Exclusion Criteria: - Households that are intending to move within the next 12 months, or that have improved flooring in any rooms or are not structurally sound.

Study Design


Intervention

Other:
Sealed washable floor plus behaviour change
Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling
Behavioral:
Behaviour change intervention
Support for behaviour change through 'floor clubs' and the provision of printed guides
Drug:
Routine deworming
Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)
Procedure:
treatment for tungiasis
Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations

Locations

Country Name City State
Kenya Dzombo ward Kwale

Sponsors (4)

Lead Sponsor Collaborator
London School of Hygiene and Tropical Medicine International Centre of Insect Physiology and Ecology (ICIPE), Jomo Kenyatta University of Agriculture and Technology, Kenya Medical Research Institute

Country where clinical trial is conducted

Kenya, 

Outcome

Type Measure Description Time frame Safety issue
Primary Enteric infections Prevalence of enteric infections (detected through PCR) in children under 5 years old will be assessed using cross-sectional stool surveys including all enrolled children under 5 years before installation of floors and 12 months after receiving the floors. Pathogens to be identified from those observed at baseline using a multipathogen panel on a subset of 100 samples. 12 months
Primary Tungiasis infections Prevalence of tungiasis (detected through clinical examination of hands and feet) in children under 15 years old will be assessed using cross-sectional clinical assessment surveys including all enrolled children under 15 years before installation of floors and 12 months after receiving the floors. 12 months
Primary STH infections Prevalence of at least one STH infection (hookworm, ascaris and trichuris infections; detected through kato katz) in all household members 12 months and older will be assessed using cross-sectional stool surveys including all enrolled people over 12 months of age before installation of floors and 12 months after receiving the floors. 12 months
Secondary Gastrointestinal illness Prevalence of gastrointestinal illness in children under 5 years - assessed in both study arms based on caregiver reported symptoms 12 months
Secondary Intensity and severity of tungiasis Intensity of tungiasis and severity of acute and chronic tungiasis-associated pathology in children <15 years - assessed using clinical severity scores (range: 0-110, high scores indicating increased severity/worse outcome) 12 months
Secondary Quality of Life for children aged 8 to 14 years Quality of Life assessed in children ages 8 to 14 years in both arms using the standardised EQ5D-Y (EuroQol 5-dimension health-related quality of life tool for children; values are anchored at 1 (full health) and 0 (a state as bad as being dead)) 12 months
Secondary Quality of Life and subjective wellbeing in primary caregivers Quality of Life assessed in primary caregivers in both arms using the standardised EQ5D tool (EuroQol 5-dimension health-related quality of life tool for adults; values are anchored at 1 (full health) and 0 (a state as bad as being dead)) 12 months
Secondary Prevalence of Ascaris lumbricoides infection Ascaris lumbricoides (roundworm) infection prevalence in all household members >1 year assessed using Kato Katz 12 months
Secondary Prevalence of hookworm infection Hookworm infection prevalence in all household members >1 year assessed using Kato Katz 12 months
Secondary Prevalence of Trichuris trichiura infection T. trichiura (whipworm) infection prevalence in all household members >1 year assessed using Kato Katz 12 months
Secondary Environmental contamination - enteric pathogens Environmental contamination for human-specific and animal faecal markers - assessed from dust/soil samples from household cooking areas and living rooms using PCR. 12 months
Secondary Environmental contamination - tungiasis Contamination of floors with eggs, larvae, pupae and adults of T. penetrans - assessed through entomology soil surveys 6 months
See also
  Status Clinical Trial Phase
Completed NCT03278431 - Triple Combinations Against Hookworm Infections in Lao Phase 4
Completed NCT01717950 - Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults Phase 1
Completed NCT02143518 - Safety and Immunogenicity Study of Na-GST-1 With or Without CpG Phase 1
Completed NCT02126462 - Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults Phase 1
Completed NCT01261130 - Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults Phase 1
Completed NCT01385189 - Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant Phase 1
Terminated NCT00473967 - Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults Phase 1
Completed NCT00603889 - Development of a Skin Test for the Na-ASP-2 Hookworm Antigen N/A
Completed NCT02839161 - Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children Phase 1
Completed NCT02476773 - Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults Phase 1
Recruiting NCT01940757 - Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae Phase 1
Completed NCT00207753 - Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections N/A
Completed NCT03373214 - Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults Phase 1
Completed NCT00939198 - Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil N/A
Active, not recruiting NCT02262403 - Hookworm Immune Regulation Project N/A
Completed NCT00120081 - Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection Phase 1